Table 2. The serum levels of MMPs and TIMPs in the four groups (ng/ml).
| Serum factors (Mean ± SD) | early AMD (n=75) | nAMD (n=89) | PCV (n=98) | Control (n=80) |
|---|---|---|---|---|
| MMP1 |
631.7±352.4* |
643.7±441.9* |
694.6±518.9* |
658.3±389.5 |
| MMP2 |
47.6±12.6* |
50.9±14.7* |
56.9±11.1† |
49.0±10.8 |
| MMP3 |
15.1±7.9* |
16.1±17.2* |
18.2±17.3* |
17.9±18.8 |
| MMP9 |
388.0±199.4* |
579.6±353.9* |
801.4±424.7‡ |
420.7±162.0 |
| TIMP1 |
190.2±189.5* |
209.7±247.8* |
215.9±218.9* |
195.8±218.6 |
| TIMP3 | 39.3±18.7* | 42.0±16.2* | 40.2±25.4* | 36.7±19.5 |
Abbreviations: MMP=Matrix metalloproteinases; TIMP=Tissue metalloproteinase inhibitors; AMD=Age-related macular degeneration; nAMD=neovascular Age-related macular degeneration; PCV=Polypoidal choroidal vasculopathy; SD=standard deviation compared with control: * p>0.05; † p<0.05; ‡ p<0.001